Abstract
Background:This study measured serum concentrations of vascular risk factors, asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) in a representative sample of older community-dwelling adults and determined their associations with objective and subjective memory impairment. Methods: Data on clinical, lifestyle, and demographic characteristics, serum ADMA, SDMA, and L-arginine (measured using LC-MS/MS) were collected from a population-based sample of older Australian adults from the Hunter Community Study. Objective memory was measured with the Audio Recorded Cognitive Screen (ARCS) neuropsychological battery and subjective memory impairment was measured using the Memory Complaint Questionnaire (MAC-Q). Results: Multivariate analysis revealed that SDMA and diabetes were significantly associated with objective memory impairment (Adjusted Odd ratio (AOR) = 3.90; 95% CI. 1.21 – 12.52 for fourth quartile (Q4) of SDMA. ADMA, SDMA, education, number of general practitioner visits and atrial fibrillation were all significantly associated with subjective memory impairment. (AOR = 1.82; 95% CI. 1.04 – 3.18 for Q4 ADMA. Conclusions: Higher serum SDMA was associated with objective and subjective memory impairment while higher serum ADMA was associated with subjective memory impairment.
Keywords: ADMA, Alzheimer’s disease, memory impairment, methylarginines, nitric oxide, older adults, SDMA.
Current Alzheimer Research
Title:Memory Impairment is Associated with Serum Methylarginines in Older Adults
Volume: 11 Issue: 1
Author(s): Mark McEvoy, Peter Schofield, Wayne Smith, Kingsley Agho, Arduino A. Mangoni, Roy L. Soiza, Roseanne Peel and John Attia
Affiliation:
Keywords: ADMA, Alzheimer’s disease, memory impairment, methylarginines, nitric oxide, older adults, SDMA.
Abstract: Background:This study measured serum concentrations of vascular risk factors, asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) in a representative sample of older community-dwelling adults and determined their associations with objective and subjective memory impairment. Methods: Data on clinical, lifestyle, and demographic characteristics, serum ADMA, SDMA, and L-arginine (measured using LC-MS/MS) were collected from a population-based sample of older Australian adults from the Hunter Community Study. Objective memory was measured with the Audio Recorded Cognitive Screen (ARCS) neuropsychological battery and subjective memory impairment was measured using the Memory Complaint Questionnaire (MAC-Q). Results: Multivariate analysis revealed that SDMA and diabetes were significantly associated with objective memory impairment (Adjusted Odd ratio (AOR) = 3.90; 95% CI. 1.21 – 12.52 for fourth quartile (Q4) of SDMA. ADMA, SDMA, education, number of general practitioner visits and atrial fibrillation were all significantly associated with subjective memory impairment. (AOR = 1.82; 95% CI. 1.04 – 3.18 for Q4 ADMA. Conclusions: Higher serum SDMA was associated with objective and subjective memory impairment while higher serum ADMA was associated with subjective memory impairment.
Export Options
About this article
Cite this article as:
McEvoy Mark, Schofield Peter, Smith Wayne, Agho Kingsley, Mangoni A. Arduino, Soiza L. Roy, Peel Roseanne and Attia John, Memory Impairment is Associated with Serum Methylarginines in Older Adults, Current Alzheimer Research 2014; 11 (1) . https://dx.doi.org/10.2174/15672050113106660178
DOI https://dx.doi.org/10.2174/15672050113106660178 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Rational Basis for Nutraceuticals in the Treatment of Glaucoma
Current Neuropharmacology Editorial [Hot Topic: Applications of Angiotensin Converting Enzyme Inhibitors and of Angiotensin II Receptor Blockers in Pharmacology and Therapy: An Update (Executive Editor: Agostino Molteni)]
Current Pharmaceutical Design Aortic Arch Calcification and Mortality in Chronic Hemodialysis Patients
Reviews on Recent Clinical Trials Type 2 Diabetes: An Atherothrombotic Syndrome
Current Molecular Medicine miR-666-3p Mediates the Protective Effects of Mesenchymal Stem Cell-derived Exosomes Against Oxygen-glucose Deprivation and Reoxygenation- induced Cell Injury in Brain Microvascular Endothelial Cells via Mitogen-activated Protein Kinase Pathway
Current Neurovascular Research The Effects of Psychotropic Drugs on the Regulation of Glucose Metabolism
Current Diabetes Reviews Bone Marrow Stem Cell Therapy for Myocardial Angiogenesis
Current Vascular Pharmacology Oxidative Stress on Progenitor and Stem Cells in Cardiovascular Diseases
Current Pharmaceutical Biotechnology Meet our Editorial Board Member
Cardiovascular & Hematological Agents in Medicinal Chemistry Relationship Between Inflammation, Insulin Resistance and Type 2 Diabetes: Cause or Effect?
Current Diabetes Reviews Pragmatic Analysis of Dyslipidemia Involvement in Coronary Artery Disease: A Narrative Review
Current Cardiology Reviews Advanced Glycation: A Novel Outlook on Atherosclerosis
Current Pharmaceutical Design Pathophysiology of Atherosclerotic Plaque Development
Cardiovascular & Hematological Agents in Medicinal Chemistry Genistein: A Boon for Mitigating Ischemic Stroke
Current Topics in Medicinal Chemistry Heart Failure and Diabetes: Perspective of a Dangerous Association
Current Hypertension Reviews Interventions Against Sarcopenia in Older Persons
Current Pharmaceutical Design Pathophysiology of Atherosclerosis: The Role of Inflammation
Current Pharmaceutical Design A Multidisciplinary Atrial Fibrillation Clinic
Current Cardiology Reviews Acute Physical Stress Increases Serum Levels of Specific microRNAs
MicroRNA Recent Progress in Pharmacological and Non-Pharmacological Treatment Options of Major Depression
Current Pharmaceutical Design